LivaNova PLC (LIVN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 707.00M USD | Liabilities, Current |
| Cash and equivalents | 516.62M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 231.30M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 172.61M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $707.00M | $516.62M | (m) | $231.30M | $172.61M | (m) |
| 2026-03-31 | (m) | $762.48M | $539.71M | (m) | $229.27M | $165.50M | (m) |
| 2025-12-31 | (m) | $808.07M | $635.55M | (m) | $215.99M | $164.70M | (m) |
| 2025-09-30 | (m) | $827.59M | $646.08M | (m) | $211.58M | $167.54M | (m) |
| 2025-06-30 | (m) | $827.10M | $593.64M | (m) | $220.19M | $165.35M | (m) |
| 2025-03-31 | (m) | $741.57M | $738.44M | (m) | $202.08M | $154.02M | (m) |
| 2024-12-31 | (m) | $392.13M | $428.86M | (m) | $193.16M | $147.57M | (m) |
| 2024-09-30 | (m) | $324.40M | $346.37M | (m) | $197.16M | $162.26M | (m) |
| 2024-06-30 | (m) | $302.99M | $329.24M | (m) | $200.89M | $154.72M | (m) |
| 2024-03-31 | (m) | $327.77M | $309.19M | (m) | $209.43M | $153.18M | (m) |
| 2023-12-31 | (m) | $334.98M | $266.50M | (m) | $215.07M | $147.89M | (m) |
| 2023-09-30 | (m) | $295.40M | $233.94M | (m) | $189.87M | $161.54M | (m) |
| 2023-06-30 | (m) | $288.16M | $222.94M | (m) | $185.88M | $156.45M | (m) |
| 2023-03-31 | (m) | $316.13M | $214.34M | (m) | $178.32M | $142.45M | (m) |
| 2022-12-31 | (m) | $297.40M | $214.17M | (m) | $183.11M | $129.38M | (m) |
| 2022-09-30 | (m) | $288.02M | $231.11M | (m) | $172.09M | $122.04M | (m) |
| 2022-06-30 | (m) | $263.89M | $109.02M | (m) | $176.95M | $119.42M | (m) |
| 2022-03-31 | (m) | $307.91M | $128.74M | (m) | $182.11M | $114.84M | (m) |
| 2021-12-31 | (m) | $696.97M | $207.99M | (m) | $185.35M | $105.84M | (m) |
| 2021-09-30 | (m) | $658.47M | $181.85M | (m) | $182.01M | $123.73M | (m) |
| 2021-06-30 | (m) | $702.25M | $329.39M | (m) | $182.18M | $127.17M | (m) |
| 2021-03-31 | (m) | $295.36M | $252.54M | (m) | $180.71M | $124.52M | (m) |
| 2020-12-31 | (m) | $309.05M | $252.83M | (m) | $184.36M | $126.67M | (m) |
| 2020-09-30 | (m) | $281.76M | $227.81M | (m) | $191.89M | $178.09M | (m) |
| 2020-06-30 | (m) | $268.36M | $232.55M | (m) | $186.14M | $177.25M | (m) |
| 2020-03-31 | (m) | $529.72M | (m) | (m) | $225.35M | $170.26M | (m) |
| 2020-01-01 | (m) | (m) | (m) | (m) | $600.00K | (m) | (m) |
| 2019-12-31 | (m) | $512.55M | $61.14M | (m) | $257.77M | $164.15M | (m) |
| 2019-09-30 | (m) | $469.19M | $75.31M | (m) | $243.18M | $167.76M | (m) |
| 2019-06-30 | (m) | $595.91M | $44.51M | (m) | $256.12M | $168.67M | (m) |
| 2019-03-31 | (m) | $622.31M | $50.78M | (m) | $247.06M | $161.27M | (m) |
| 2018-12-31 | (m) | $496.75M | $47.20M | (m) | $256.13M | $153.53M | (m) |
| 2018-09-30 | (m) | $347.07M | $79.95M | (m) | $252.30M | $153.06M | (m) |
| 2018-06-30 | (m) | $368.02M | $47.38M | (m) | $261.92M | $157.83M | (m) |
| 2018-03-31 | (m) | $459.48M | $64.96M | (m) | $279.83M | $154.33M | (m) |
| 2017-12-31 | (m) | $406.02M | $93.61M | (m) | $282.14M | $144.47M | (m) |
| 2017-09-30 | (m) | $356.36M | $65.16M | (m) | $314.04M | $214.59M | (m) |
| 2017-06-30 | (m) | $342.45M | $42.69M | (m) | $305.36M | $204.68M | (m) |
| 2017-03-31 | (m) | $323.83M | $62.72M | (m) | $271.53M | $192.39M | (m) |
| 2016-12-31 | (m) | $316.81M | $39.79M | (m) | $275.73M | $183.49M | (m) |
| 2016-09-30 | (m) | $316.89M | $63.63M | (m) | $284.35M | $197.65M | (m) |
| 2016-06-30 | (m) | $343.91M | $63.89M | (m) | $299.63M | $192.73M | (m) |
| 2016-03-31 | (m) | $381.55M | $87.47M | (m) | $288.54M | $210.76M | (m) |
| 2015-12-31 | (m) | $359.12M | $112.61M | (m) | $272.35M | $212.45M | (m) |
| 2015-10-18 | (m) | $71.01M | $189.78M | (m) | $45.57M | $25.94M | (m) |
| 2015-09-30 | (m) | $0.00 | $0.00 | (m) | $76.00K | (m) | (m) |
| 2015-07-24 | (m) | (m) | $162.36M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2015-04-24 | (m) | $31.45M | $124.19M | (m) | $50.57M | $23.96M | (m) |
| 2015-02-20 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2015-01-23 | (m) | (m) | $116.21M | (m) | (m) | (m) | (m) |
| 2014-10-24 | (m) | (m) | $116.84M | (m) | (m) | (m) | (m) |
| 2014-04-25 | (m) | (m) | $103.30M | (m) | (m) | (m) | (m) |
| 2014-04-24 | (m) | (m) | $124.19M | (m) | (m) | (m) | (m) |
| 2013-04-26 | (m) | (m) | $120.71M | (m) | (m) | (m) | (m) |
| 2012-04-27 | (m) | (m) | $96.66M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |